Reviews
Provider reviews
Everyone else reviews these companies on price and delivery speed. We ask four questions instead: what regulatory category is the thing in the vial, has the molecule been tested in a human for the use it is sold for, do the marketing claims survive the trials, and who is actually licensed to fill the prescription.
No scores and no stars. Companies we have a paid relationship with are listed first, and we say so here rather than marking individual rows; everyone else follows, and within both groups the order is alphabetical. Being a partner changes where a company sits, never a single number printed beside it. Our editorial policy sets out how a claim is checked; our disclosure sets out the one thing commission is never allowed to reach.
Published
Every review on this site
Showing 94 of 94 reviews
Bodybuilding Health+ names two physicians and four pharmacies, then says full results develop in two to three months. The trials ran 68 and 72 weeks.
BreezeMeds sells semaglutide and tirzepatide, which have real trials, alongside NAD+ and sermorelin, which do not. Here is what the evidence actually shows.
CareBareRX is the only seller here that cites a trial on a product page and quotes it accurately. Four of its "starting at" prices are refuted by its catalog.
Collective's trial figures are accurate. Its weight-loss calculator runs on a higher one it does not source.
CoreAge's NAD+ page promises help for "men with ED unresponsive to PDE5 inhibitors" — on a coenzyme sold for energy. No trial backs its sermorelin timeline.
DirectMeds sells sermorelin under the heading "Clinically Proven Peptide Therapy". No trial registry holds a single record naming the molecule.
DudeMeds argues against compounded testosterone in detail, then sells compounded semaglutide described as an Ozempic generic and an FDA-approved medication.
Eden sells approved Wegovy at $1,695 and compounded sermorelin at $126 from the same cart. The evidence behind those two numbers is not comparable.
Embody sells "GLP-1 Injections" from $79/month and never writes the words semaglutide or tirzepatide anywhere on its homepage.
Enhance.MD prints the real interval beside the label: its "12-month" NAD+ plan is billed every 48 weeks, and its "1-month" plan every four.
Found credits "up to 15-20% weight loss" to Wegovy and Zepbound by name, not to its compounded products — and publishes no state list at all.
Gala's $179/month is a yearly-prepay rate — it says so. The standing price is $299 on a four-week cycle, and its "12-month" plan ships 48 weeks.
He & She MD barely claims anything about efficacy, and its one outcome figure is its own self-reported data. The pricing is where the real problem sits.
HealthRX cites STEP 1 at 68 weeks and the tirzepatide phase 3 at 72 weeks, with the right figures — the most accurate claim set we graded this month.
HumeCare+ says its patients average 21.5% weight loss in 10 months — more than either GLP-1 trial found. The number is its own, and unpublished.
Live Vital publishes 156 PubMed-keyed study summaries and links none of them from any product page. Eleven of its fourteen products cite nothing at all.
Luvo Health puts first improvements at months four to six, which fits the trials. Its longevity program names no compound at all.
MangoRx names its pharmacy — Epiq Scripts — which almost nobody does. Its Terms then make you waive the right to any other, while its FAQ says you have it.
MEDGm's own FAQ says a BMI of 20 makes you likely a great candidate. No trial enrolled anyone near that.
MyDrHank's GLP-1 page labels 14.9% as tirzepatide's trial result. Its own footnote, on that same page, cites 20.9% for tirzepatide.
Oak sells sermorelin, tesamorelin, NAD+ and glutathione with no product page at all. The only thing it publishes about each is a name and a price.
Pallas names six pharmacies with phone numbers and says NAD+ research "is still developing" — then divides a 12-week cycle by three to get a monthly price.
RxSpan MD lists compounded semaglutide at $249 and never says whether that is a month, a quarter or a single vial. It also names its physician.
Sesame's Wegovy pill claim sits under its own trial at 14%. One variant of its weight-loss page says 25%, with no drug, dose or source named.
Shed states its GLP-1 results with both placebo arms and the compounded disclaimer, then sells sermorelin at $199 on claims its trials never tested.
SkinnyRx holds an open FDA misbranding letter naming its compounded GLP-1s. Its page still says the medication is "Prepared in FDA-compliant facilities".
SnagRx promises "up to 15% of your body weight (1-2lbs per week)". STEP-1 averaged about 0.23% a week — a quarter to a half of that rate.
FDA wrote to Sprout Health about a single sentence claiming GLP-1s are FDA-approved. The sentence is gone; the letter is still open.
Strut's NAD+ page calls the coenzyme "a peptide that signals your own pituitary gland". No trial tests what its flagship peptide promises.
Synergy Rx sells five different peptides at $275 each and leads with "The Proven Way to lose 15% of your body weight fast" — with nothing cited.
Trimi names SURMOUNT-1 and SELECT, says they tested the ingredients not its product, names two 503A pharmacies with a license number, and offers a COA.
Try Ageless sells sublingual tirzepatide drops at $199/mo. Zero completed trials test tirzepatide by that route — against 91 that test the injection.
WellMedr sells tirzepatide co-formulated with NAD+ and B12 as "Energy & Focus+", for cognitive output rather than weight. No trial has tested the combination.
yourEra advertises compounded GLP-1 from $79.20 a month. That is the six-month plan, already 20% discounted, and no one-month price is published.
1st Optimal publishes its 503A pharmacy by name and address — and names only two peptide molecules across 213 pages and 90 million characters.
AgelessRx sponsors ten registered trials and published PEARL. Its primary endpoint was null — and the biggest number on the page is a customer survey.
AHBARx writes "may support" where others write "supports". The hedging is real and it does not change what has been tested.
Alan advertises a low headline rate on a two-month prepay. Its longer plans cost more per month, not less — the reverse of the usual shape.
Alinwell publishes certificates of analysis, which almost nothing here does. It also gives eight blends a description belonging to one ingredient.
Andrew Meds sells two peptide products and asserts no outcome for either. Its signup screens are a different matter.
Auren Rx names its pharmacy and prints FDA's own compounding disclaimer on every page — then sells collagen, sleep and clarity the trials do not support.
Believe Health sells a peptide menu identical to Alinwell's and Longevixx's. It undercuts both on BPC-157 and publishes no certificate of analysis.
Belle sells sermorelin, NAD+ and glutathione alongside GLP-1s, and claims almost nothing for any of them. That restraint is the finding.
Bliv quotes four different entry prices on a single page and names its pharmacy only inside the telehealth consent form. Here is what each figure buys.
Clume sells NAD+ and sermorelin as "Molecular Cellular Optimization" — and misspells the drug on the card.
Defy is a real Tampa clinic with a named medical director. Its Peptide Therapy page names no peptide, and it calls sermorelin FDA-approved.
Edessa publishes an 18% average weight loss, a 93% maintenance rate and a 6.5-inch waist reduction under a "clinical data" heading. None carries a source.
We completed Eviora MD's signup — twenty-eight screens including date of birth and shipping address — and were never shown a price at any step.
Fella sources its weight-loss average to its own members, not a trial. Its quiz then quotes a higher average — and no GLP-1 price appears anywhere.
GOAL.MD prices every GLP-1 dose the same and prints the arithmetic. Its one wrong claim is that FDA monitors the pharmacies compounding it.
We walked all 29 Goldspan product pages. One of them tells tirzepatide buyers they are getting semaglutide.
Hone sells compounded PT-141 to men at $130/mo. The FDA label for the approved version says it is not indicated in men, or to enhance performance.
Idgie Health publishes no weight-loss figure at all. Its terms describe a membership fee that appears on none of its pricing pages.
Invigor names all five compounding pharmacies it uses — a rare disclosure. Its GLP-1 pages never once say semaglutide or tirzepatide.
Joi + Blokes sells sermorelin and VIP with numbers attached — 5-10% body fat, 10% lean muscle. No trial in either literature reports them.
Lean Meds says sleep improves in 2 weeks and body composition by month 3. No trial measured either.
Lighter You now names sermorelin and NAD+ and prices them. Its own TidesRx pages price the same three products lower than its home page does.
Longevixx sells a peptide menu identical to Alinwell's, card for card. It publishes no certificate of analysis, names no pharmacy and has no refund policy.
LumiMeds advertises three low entry rates and publishes no rung behind them. Its membership terms are non-cancelable and non-refundable mid-term.
Not one of Magnolia's 24 product pages says what the product does. The category label does it instead.
Marek Health names all seven pharmacies that fill its prescriptions — and ships a 13-peptide catalog to your browser that no page on the site will show you.
Maximus fixed the four claims FDA cited in June 2026. Its newest peptide rests on an unpublished, uncontrolled study the company ran on itself.
Mondae describes its three peptides in one line each. One names a mechanism trials measured; the other two name nothing a trial could.
NEUVÉ publishes eleven priced peptide protocols and says they are compounded by "503A and 503B certified" pharmacies. No such certification exists.
New Wave Health publishes its company, address and terms — then runs a twenty-eight screen signup that never shows a price at any point.
Nex Gen names Manifest Pharmacy, which few sellers do. It also badges every product "503A accredited pharmacies" — a designation that does not exist.
No BS RX names all four pharmacies that might fill your prescription, with addresses and phone numbers, and states the compounding tier on every plan.
Nova's tesamorelin page cites real trials for visceral fat and never mentions who was in them.
Novo Nordisk's direct pharmacy sells approved semaglutide with published NDCs and phase 3 evidence. It also calls itself FDA-approved, which no pharmacy is.
We counted every page. Oria never names semaglutide or tirzepatide anywhere on its public site.
Peak Wellness names the pharmacy that compounds its GLP-1s, which is rare and useful. It also turns a trial's best-case result into an average.
PeptidesRx names its pharmacy — then states it cannot dispense sterile compounds, while every injectable page claims an FDA-registered 503B facility.
Polly lists six treatments at one flat price each, same price at every dose. Its refund policy is where the six-month plan appears.
Prime Doctor RX publishes no weight-loss percentage, no timeline and no before-and-after. Its clinical copy is a series of refusals to promise anything.
Regenics sells twelve peptides to members only. FDA names all twelve on its page of bulk substances that may present significant safety risks.
Rehydra+ still lists BPC-157, KPV and MOTS-c on its site. Every one of those pages now redirects to a login. Here is what it will actually sell you.
Renlo Health attributes its weight-loss figures to STEP 1 and SURMOUNT-1 by name, labels them averages, and publishes no timeline to get wrong.
RX Bella cites STEP 1 and SURMOUNT-1 by name, then places their 68- and 72-week results at month six — and credits a diabetes trial for weight maintenance.
Rx.com names its dispensing pharmacy with an address, names its clinical network, and makes no weight-loss claim anywhere on its GLP-1 pages.
Science & Co shows a 222-to-189-pound example and calls it 15% on average. That matches STEP 1's mean almost exactly — and no trial is named.
SexyMD's microdose page says twice a week in one place and once weekly in another.
Solaya publishes a provider number that resolves in the federal registry — and no price for any peptide.
Superior Remedies puts semaglutide's ~15% at month 6. STEP 1 measured it at week 68 — about 15.6 months. It also cites a diabetes trial family.
telos rx sells ten peptides and hedges every claim as "studied for". Its BPC-157 FAQ answers the obvious question with "We cannot say that."
The Edit names its pharmacy, its practice and its regulatory category — then markets sermorelin for sleep and NAD+ for focus. The trials say otherwise.
TOM says compounded medications are not FDA-approved and carry additional risks, names five pharmacies with prices, and quotes one membership three ways.
Transcend names four pharmacies and publishes the compounded-drug disclaimer on one page — while another page still calls tesofensine a peptide.
Trava sells GLP-1s “tested in FDA approved labs”. No such approval exists, and no test result is published anywhere on the site.
Trellis names its pharmacy and names the doctor in charge, license and all. It also sells injectable NAD+ and glutathione on claims no human trial supports.
Valhalla sells GLP-1 (T) and GLP-1 (S). It never writes tirzepatide or semaglutide in any copy a reader can see, and hides every price behind a login.
VAULT sells ten prescription peptides with published doses — under a Terms of Service that says its products are not intended to treat any disease.
VevaRX discloses more than any seller here and its NAD+ page still shows three different prices.
Vyvron sells injectable sermorelin and NAD+ at $229. Its entire site contains no mention of USP, sterility, potency or a certificate of analysis.
Wellorithm's quiz tells you to expect 3.75 to 4.17 pounds a week and a ten-week finish. The landmark trial averaged under half a pound a week.